ArticleJACC. Heart failure2026
Refining the Definition for "Low Risk" in Pulmonary Arterial Hypertension: Time to Reduce Morbidity and Mortality.
Article in JACC. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Risk Scores: Translating PAH Risk Assessment into Clinical Benefit. Comment on Cortes-Telles et al. Sequential Add-On Therapy Modifies Mortality Risk Stratification in Group 1.4 Pulmonary Arterial Hypertension: A Real-World, Single-Center Retrospective Cohort Study from Mexico.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
background"Low-risk" pulmonary arterial hypertension (PAH) patients are defined as having a risk of death <5% within 1 year. As treatment improves, accounting for the negative impact of short-term morbidity and considering extending the duration of <5% mortality in this definition seem prudent.
objectivesThis study sought to propose a more stringent definition of low risk that extends the low mortality risk to 3 years and specifies a low risk of morbidity at 1 year.
methodsThis study used patient-level data from a harmonized data set of 8 PAH randomized controlled trials that included patients with a REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) 2.0 risk score ≤6 (ie, low risk using contemporary scores). Low risk was a priori defined as "risk of death <5% at 3 years and risk of clinical worsening <10% at 1 year." Clinical worsening was defined at the individual trial level and included any of the following: lung transplantation, hospitalization for PAH, initiation of long-term oxygen therapy, 15% decrease in 6-minute walking distance (6MWD) from baseline with a worsening of NYHA functional class, or the addition of a new PAH medication.
resultsA total of 1,925 PAH patients were included: median age, 46 years (Q1-Q3: 34-57 years); mean pulmonary artery pressure, 47 mm Hg (Q1-Q3: 37-58 mm Hg); pulmonary vascular resistance, 8 WU (Q1-Q3: 6-12 WU), 6MWD, 409 m (Q1-Q3: 363-423 m); and N-terminal pro-B-type natriuretic peptide, 227 pg/mL (Q1-Q3: 101-621 pg/mL). Compared with patients with a REVEAL 2.0 score equal to 5 or 6, patients with a score ≤4 had a better clinical and hemodynamic presentation and met the definition of "refined low risk" (3-year mortality of 2.6% and 1-year clinical worsening of 6.4%). Idiopathic PAH, 6MWD, N-terminal pro-B-type natriuretic peptide, NYHA functional class I to II, heart rate, and the absence of previous atrial fibrillation were associated with refined low risk.
conclusionsThis study is the first to embed both morbidity and mortality within the definition of low -risk for PAH and suggests that patients with a REVEAL 2.0 risk score ≤4 define this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.